Evidence map›Paper›PMID 38134305›Full record

Trial reportThe Journal of infectious diseases2024

Seroreversion to Chlamydia trachomatis Pgp3 Antigen Among Children in a Hyperendemic Region of Amhara, Ethiopia.

Christine Tedijanto, Solomon Aragie, Sarah Gwyn, Dionna M Wittberg, Taye Zeru, Zerihun Tadesse, Ambahun Chernet, Isabel J B Thompson, Scott D Nash, Thomas M Lietman and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02754583 (Sanitation, Water, and Instruction in Face-washing for Trachoma I/II), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02754583 phase3completednot on this map

Sanitation, Water, and Instruction in Face-washing for Trachoma I/II

TypeinterventionalSponsorUniversity of California, San FranciscoRan2015 to 2024Enrolled47,605ConditionsTrachomaArmsWater, sanitation, and hygiene (WASH) intervention, Standard of care WASH intervention, Azithromycin, Tetracycline, Control
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Data Resource Profile: Global Trachoma Serology Data Repository.International journal of epidemiology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Monitoring transmission intensity of trachoma with serology.medRxiv : the preprint server for health sciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Christine TedijantoFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-3403-5765
Solomon AragieThe Carter Center Ethiopia, Addis Ababa, Ethiopia.ORCID 0000-0003-4967-9627
Sarah GwynDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-1856-3165
Dionna M WittbergFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9887-5993
Taye ZeruAmhara Public Health Institute, Bahir Dar, Ethiopia.ORCID 0000-0003-0736-2955
Zerihun TadesseThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Ambahun ChernetThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Isabel J B ThompsonFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Scott D NashThe Carter Center, Atlanta, Georgia, USA.ORCID 0000-0001-5741-8537
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-8216-0240
Diana L MartinDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jeremy D KeenanFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7118-1457
Benjamin F ArnoldFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-6105-7295

Funding

Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)UG1EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2019 to 2023
$4.1M
Seroepidemiology of trachoma for the elimination endgameR01AI158884 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARNOLD, BENJAMIN F · 2021 to 2025
$2.0M
AbbottNational Institute of Allergy and Infectious Disease R01-AI158884NEI NIH HHS UG1 EY023939NEI NIH HHS UG1-EY023939NIAID NIH HHS R01 AI158884
6 · The paper itself

Abstract

Monitoring trachoma transmission with antibody data requires characterization of decay in IgG to Chlamydia trachomatis antigens. In a 3-year longitudinal cohort in a high-transmission setting, we estimated a median IgG half-life of 3 years and a seroreversion rate of 2.5 per 100 person-years (95% confidence interval, 1.6-3.5). Clinical Trials Registration NCT02754583.

Indexed as

Antibodies, BacterialAntigens, BacterialBacterial ProteinsChlamydia trachomatisImmunoglobulin GTrachomaChildChild, PreschoolEndemic DiseasesEthiopiaFemaleHumansInfantLongitudinal StudiesMaleAntibodies, BacterialAntigens, BacterialBacterial ProteinsImmunoglobulin Gpgp3 protein, ChlamydiaantibodyChlamydia trachomatisEthiopiaIgGseroepidemiologytrachoma

Identifiers

PMID38134305
PMCPMC11326833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.